Normal view MARC view ISBD view

Dual antiplatelet therapy for acute coronary syndromes: How long to continue?. [Review]

MedStar author(s):

Citation: Cleveland Clinic Journal of Medicine. 83(9):675-88, 2016 SepPMID: 27618356Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Acute Coronary Syndrome/dt [Drug Therapy] | *Platelet Aggregation Inhibitors/pd [Pharmacology] | Drug Therapy, Combination/mt [Methods] | Humans | Medication Therapy Management/st [Standards] | Time FactorsYear: 2016 Local holdings: Available online through MWHC library: 2001- 2010, Available in print through MWHC library: 2002 - presentISSN:

0891-1150

Name of journal: Cleveland Clinic journal of medicineAbstract: Copyright � 2016 Cleveland Clinic.For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy. All authors: Halkar M, Lincoff AMFiscal year: FY2017Digital Object Identifier:

https://dx.doi.org/10.3949/ccjm.83a.15092

Date added to catalog: 2017-05-24

Holdings ( 1 )
Title notes ( 4 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	27618356	Available		27618356

Available online through MWHC library: 2001- 2010, Available in print through MWHC library: 2002 - present

For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.

English